• PCV15 - DRUGS FOR TREATING SEVERE HYPERTENSION IN PREGNANCY- A NETWORK META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PSS23 - SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS

    Oct 1, 2018, 00:00

  • PHP65 - ANALYSIS OF ICER-ESTIMATED VALUE-BASED PRICES AND POTENTIAL DISCOUNTS FOR DRUGS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN335 - TIME TRENDS IN FRONTLINE SYSTEMIC THERAPY UTILIZATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PUK30 - THE BURDEN ASSOCIATED WITH COMPLEMENT 3 GLOMERULOPATHY (C3G)

    Oct 1, 2018, 00:00

  • PHP192 - HTA EDUCATIONAL NEEDS IN CENTRAL-EASTERN-SOUTH EUROPEAN (CESE) COUNTIRES – RESULTS OF JOC HTA PROJECT

    Oct 1, 2018, 00:00

  • PMU120 - ASSESSING THE RISK FACTORS OF COMPLICATIONS RELATED TO PERIPHERAL INTRAVENOUS CANNULAS

    Oct 1, 2018, 00:00

  • PND147 - WALKING DISORDERS IN MS- HOW DO THEY IMPACT PATIENTS’ QUALITY OF LIFE? RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PRM158 - PREDICTIVE BIOMARKERS OF TREATMENT SUCCESS IN ADVANCED NON–SMALL CELL LUNG CANCER PATIENTS USING MULTIVARIATE CAUSAL INFERENCE.

    Oct 1, 2018, 00:00

  • PGI9 - SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF INFLIXIMAB BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PMU29 - EVALUATING BUDGET IMPACT ANALYSES FOR EXTRAMURAL DRUGS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PDB117 - CHANGES IN PATIENT REPORTED OUTCOMES, ATTITUDES AND HEALTH BEHAVIORS IN 606 PEOPLE WITH DIABETES FOLLOWING 2 MONTHS USE OF THE DRUGSTARS HEALTH APP

    Oct 1, 2018, 00:00

  • PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE

    Oct 1, 2018, 00:00

  • PND141 - CHARACTERISTICS AND MANAGEMENT OF MIGRAINE PATIENTS WHO HAVE FAILED PRIOR PREVENTIVE TREATMENT IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTS

    Oct 1, 2018, 00:00

  • PCP25 - ARTIFICIAL INTELLIGENCE ASSISTED LITERATURE REVIEWS- KEY CONSIDERATIONS FOR IMPLMENTATION IN HEALTH CARE RESEARCH

    Oct 1, 2018, 00:00

  • PSS37 - A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS

    Oct 1, 2018, 00:00

  • PIN106 - GETTING CLOSER TO THE GOAL- MEASUREMENT OF THE 90 90 90 TARGETS TO END THE AIDS EPIDEMIC IN THE COLOMBIAN HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • AD2 - A FULLY INTEGRATED CLINICAL TRIAL LIKE SYSTEM TO GUARANTEE PERSISTENCE ON PLANNED HEPATITIS C TREATMENT- EVIDENCE FROM THE REAL-WORLD

    Oct 1, 2018, 00:00

  • PHP69 - A REVIEW OF FUNDING PATHS FOR E-HEALTH SOLUTIONS IN THE EU5, US AND CANADA

    Oct 1, 2018, 00:00

  • PIH48 - CAN OLDER USERS USE ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOA)?

    Oct 1, 2018, 00:00

  • PIN102 - IMPACT OF DEPRESSION AND ITS ASSOCIATION TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ADHERENCE AND ADVERSE DRUG REACTIONS IN PEOPLE LIVING WITH HIV IN INDIA

    Oct 1, 2018, 00:00

  • PSY209 - PATIENT NEEDS, PERCEPTIONS AND ATTITUDINAL DRIVERS ASSOCIATED WITH OBESITY- A QUALITATIVE ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PHP94 - DOES THE ORPHAN DESIGNATION INCREASE THE CHANCES OF POSITIVE HTA OPINION IN FRANCE, GERMANY AND UK?

    Oct 1, 2018, 00:00

  • PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS- A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.

    Oct 1, 2018, 00:00

  • PMS40 - COST – EFFECTIVENESS STUDY OF ETANERCEPT AS FIRST LINE TREATMENT FOR ANKYLOSING SPONDYLITIS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PRM72 - PERFORMANCE OF AUTOMATED SCREENING OF CITATIONS COMPARED TO HUMAN REVIEWERS IN SYSTEMATIC LITERATURE REVIEWS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND42 - BURDEN OF MULTIPLE SCLEROSIS IN RUSSIA AND EUROPE

    Oct 1, 2018, 00:00

  • PHP197 - AN EVALUATION OF THE PERFORMANCE OF HOSPITAL PHARMACIES’ GROUP PURCHASING ORGANIZATION TO PROMOTE HEALTHCARE MANAGEMENT

    Oct 1, 2018, 00:00

  • PGI45 - RELIABILITY AND VALIDITY OF A NEW PATIENT-REPORTED OUTCOME FOR GASTROPARESIS

    Oct 1, 2018, 00:00

  • CN1 - VALIDATING SURVIVAL EXTRAPOLATIONS IN FIRST LINE TREATMENT OF RENAL CELL CARCINOMA USING LITERATURE-BASED CONDITIONAL SURVIVAL PROBABILITIES

    Oct 1, 2018, 00:00

  • PIN22 - A PAYER PERSPECTIVE OF THE HOSPITAL INPATIENT ADDITIONAL CARE COSTS OF ANTIMICROBIAL RESISTANCE IN FRANCE- A MATCHED CASE-CONTROL STUDY

    Oct 1, 2018, 00:00

  • PRS32 - IMPACT OF SEVERE ASTHMA IN FRANCE- A CLAIM DATABASE STUDY

    Oct 1, 2018, 00:00

  • PMU30 - BUDGET AND HEALTH IMPACT OF IMMUNO-ONCOLOGY TREATMENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRM183 - DEVELOPMENT OF A FIT-FOR-PURPOSE TOBACCO AND NICOTINE PRODUCTS DEPENDENCE INSTRUMENT

    Oct 1, 2018, 00:00

  • PSY147 - AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRM137 - MODELING THE DISTRIBUTION OF TBEV-INFECTED TICKS IN GERMANY TO ESTIMATE TBE-INFECTIONS IN HUMANS

    Oct 1, 2018, 00:00

  • PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)- PATIENTS’, ONCOLOGISTS’ AND NURSES’ PERSPECTIVES

    Oct 1, 2018, 00:00

  • PRM223 - THE MISSING DATA PROBLEM- USING PROPENSITY SCORES TO ESTIMATE NON-RANDOMISED TREATMENT EFFECTS WITH MISSING COVARIATE DATA

    Oct 1, 2018, 00:00

  • PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PND13 - REAL WORLD EVIDENCE (RWE) ON IMPACT OF AGE ON LONG-TERM PERSISTENCE TO DISEASE MODIFYING THERAPIES (DMTS) IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN AUSTRALIA

    Oct 1, 2018, 00:00

  • PHP14 - CO-CREATION OF PATIENT ENGAGEMENT QUALITY GUIDANCE AND QUALITY CRITERIA FOR MEDICINES DEVELOPMENT- AN INTERNATIONAL MULTI-STAKEHOLDER INITIATIVE

    Oct 1, 2018, 00:00

  • PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PSY72 - COST OF ILLNESS ANALYSIS- ECONOMIC BURDEN IN DIRECT COSTS OF OBESITY-RELATED CO-MORBIDITIES – STROKE, MYOCARDIAL INFARCTION, TYPE 2 DIABETES - IN RUSSIA

    Oct 1, 2018, 00:00

  • PHP195 - DO COMPANIES’ MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY’S COMPLEX PAYER MARKETPLACE?

    Oct 1, 2018, 00:00

  • PRM126 - A COMPARISON OF MIXTURE CURE AND STANDARD PARAMETRIC MODELING TO ESTIMATE LONG-TERM SURVIVAL FOR SMALL-CELL LUNG CANCER IN PATIENTS TREATED WITH NIVOLUMAB AFTER PROGRESSION

    Oct 1, 2018, 00:00

  • PRM18 - REAL-WORLD DATA (RWD) COLLECTION ALONGSIDE EARLY ACCESS TO MEDICINES SCHEMES (EAMS) - NIVOLUMAB IN GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJ) AFTER TWO OR MORE PRIOR THERAPIES

    Oct 1, 2018, 00:00

  • PMH51 - HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG COMMUNITY-DWELLING SUBJECTS WITH SCHIZOPHRENIA TREATED WITH RBP-7000 IN A CLINICAL TRIAL SETTING OVER 12 MONTHS

    Oct 1, 2018, 00:00

  • PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICE

    Oct 1, 2018, 00:00

  • PMU33 - ESTIMATING THE COST OF A CAESAREAN SECTION IN A PUBLIC HOSPITAL IN CYPRUS

    Oct 1, 2018, 00:00

  • PMU23 - ANALYSIS OF PATIENT SAFETY INCIDENTS REPORTS AT A UNIVERSITARY HOSPITAL

    Oct 1, 2018, 00:00

  • PMD39 - BUDGET IMPACT ANALYSIS TO TAKE DECISIONS ABOUT TIME OF INVESTMENT RECOVERY IN IMPLANTABLE MEDICAL DEVICES- TRABECULAR MICRO-BYPASS STENT IN OPEN-ANGLE GLAUCOMA

    Oct 1, 2018, 00:00

  • PRM2 - IDENTIFICATION OF DOSE-ESCALATION IN BIOLOGIC THERAPY BASED ON CLAIMS DATA- THE EXAMPLE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

    Oct 1, 2018, 00:00

  • PRS89 - MEASUREMENT OF MAINTENANCE AND RELIEVER USE IN ASTHMA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PMS94 - AVAILABILITY OF TOOLS TO ASSESS PROMS IN HIP ARTHROPLASTY IN SPAIN. A SYSTEMATIC REVIEW.

    Oct 1, 2018, 00:00

  • PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L- COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE

    Oct 1, 2018, 00:00

  • PSS63 - IDENTIFYING PATIENT PREFERENCES FOR GLAUCOMA TREATMENT- EVIDENCE FROM LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP171 - REVISITING REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY- 2016-2018

    Oct 1, 2018, 00:00

  • PCP35 - A MODERN MEDICAL KNOWLEDGE IN MANAGEMENT OF PATIENTS WITH INFLUENZA IN UKRAINE

    Oct 1, 2018, 00:00

  • PUK11 - ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE RELATED COMPLICATIONS AND THERAPIES IN CHINA- QUANTIFYING THE COSTS OF CARDIOVASCULAR EVENTS, BLOOD TRANSFUSION FOR ANEMIA AND DIALYSIS

    Oct 1, 2018, 00:00

  • PHP42 - EARLY ACCESS PROGRAMS- A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSS65 - DEVELOPMENT OF THE NEUROTROPHIC KERATOPATHY QUESTIONNAIRE- QUALITATIVE RESEARCH

    Oct 1, 2018, 00:00

  • PCN334 - OUTCOMES OF PERIPHERAL T-CELL LYMPHOMA (PTCL) PATIENTS TREATED IN THE REAL WORLD

    Oct 1, 2018, 00:00

  • PMU25 - EXAMINING THE CONSISTENCY AND ACCURACY OF THE BUDGET IMPACT MODELS SUBMITTED TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND TO AID THE CREATION OF AN APPLICANT TEMPLATE

    Oct 1, 2018, 00:00

  • PSY124 - COST OF ALLOGENEIC HSCT COMPLICATIONS IN BRAZIL- A DETERMINISTIC LINKAGE APPROACH FOCUSING ON PATIENTS WITH GVHD

    Oct 1, 2018, 00:00

  • HT6 - DO SPAIN AND PORTUGAL EVALUATORS AND DECISION MAKERS GIVE THE SAME IMPORTANCE TO EVALUATION CRITERIA OF INNOVATIVE MEDICINES?

    Oct 1, 2018, 00:00

  • PSY59 - ORPHAN DRUGS PRICES COMPARISON IN MIDDLE EAST NORTH AFRICA (MENA) REGION

    Oct 1, 2018, 00:00

  • PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDY

    Oct 1, 2018, 00:00

  • PSY83 - IMPACT OF DOSE ESCALATION ON AVERAGE COST AND COST-EFFECTIVENESS OF ANTI-TNF AND USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN

    Oct 1, 2018, 00:00

  • PCN34 - PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC – A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY44 - TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS- A BUDGET IMPACT ANALYSIS IN ITALY

    Oct 1, 2018, 00:00

  • PHP56 - EARLY ACCESS PROGRAMS- AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALY

    Oct 1, 2018, 00:00

  • PSS74 - PATIENT QUALITY OF LIFE AND SATISFACTION IN AN APREMILAST-TREATED PSORIASIS POPULATION- ANALYSIS OF 126 PATIENTS FROM THE APPRECIATE STUDY IN THE UNITED KINGDOM AND IRELAND

    Oct 1, 2018, 00:00

  • PDB90 - ASSOCIATION BETWEEN SULFONYLUREA (SU) TREATMENT AND TRAFFIC ACCIDENTS IN DENMARK

    Oct 1, 2018, 00:00

  • Copyright/Subscription

    Oct 1, 2018, 00:00

  • PHP316 - EXPLORING BIOSIMILAR MARKET ACCESS CONSIDERATIONS ACROSS THE EU

    Oct 1, 2018, 00:00

  • PSY118 - RESOURCE USE AMONG BIOLOGICAL THERAPY INITIATORS WITH CROHN’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PCV56 - CLINICAL AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE AND VALUE OF EVOLOCUMAB TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PRM88 - THE ADVANCEMENT OF TOOLS FOR AUTOMATING DATA EXTRACTION IN SYSTEMATIC REVIEWS

    Oct 1, 2018, 00:00

  • PRM14 - USING EXPERT ELICITATION TO CAPTURE COST-EFFECTIVENESS MODEL UNCERTAINTIES- VALUING EXPERTS' CONTRIBUTION

    Oct 1, 2018, 00:00

  • PCN15 - INVESTIGATION OF THE ASSOCIATION BETWEEN INCIDENT METFORMIN EXPOSURE AND NON-SMALL CELL LUNG CANCER DIAGNOSIS AMONG DIABETIC PATIENTS

    Oct 1, 2018, 00:00

  • PHP209 - FUNDING OF CLINICAL TRIALS IN UNIVERSITY HOSPITAL ENVIRONMENT

    Oct 1, 2018, 00:00

  • PMD153 - TURKISH PUBLIC PROCUREMENT SYSTEM FOR MEDICAL DEVICES- IS THERE ROOM FOR IMPROVEMENT WHEN VALUING QUALITY?

    Oct 1, 2018, 00:00

  • PRM34 - FRENCH EFFICIENCY OPINIONS OF THE ECONOMIC AND PUBLIC HEALTH COMMITTEE (CEESP)- IS THERE AN IMPACT ON THE MARKET ACCESS FOR INNOVATIVE DRUGS?

    Oct 1, 2018, 00:00

  • PMS25 - COST COMPARISON OF OPEN, MINIMALLY INVASIVE AND GUIDE-WIRELESS MINIMALLY INVASIVE SURGERY TRANSFORAMINAL LUMBAR INTERBODY FUSION (GMIS/TLIF) INTERVENTION FOR LUMBAR DEGENERATIVE DISC DISEASE IN THE UK

    Oct 1, 2018, 00:00

  • PIN20 - A COST-EFFECTIVENESS ANALYSIS OF THE INFLUENZA VACCINE IN ADULT PATIENTS WITH CANCER

    Oct 1, 2018, 00:00

  • PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORT

    Oct 1, 2018, 00:00

  • PMD9 - ANALYSIS OF DYSLIPIDEMIA AMONG PATIENTS WITH DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PIH25 - BE AWARE OF PEDIATRIC MALNUTRITION AT ADMISSION! ECONOMIC CONSEQUENCES OF DIFFERENT HOSPITAL SCREENING AND NUTRITIONAL TREATMENT APPROACHES.

    Oct 1, 2018, 00:00

  • PMD145 - CHARACTERIZING BURDEN OF INTRAOPERATIVE AND EARLY POSTOPERATIVE PERIPROSTHETIC HIP FRACTURES FOLLOWING TOTAL HIP ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PIN93 - REAL-WORLD TIGECYCLINE USE IN CHINA FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS)

    Oct 1, 2018, 00:00

  • PSY172 - REAL WORLD EVIDENCE OF HEREDITARY HYPOPHOSPHATEMIA IN GERMANY – ANALYSIS OF GERMAN SHI CLAIMS DATA FOR PEDIATRIC PATIENTS

    Oct 1, 2018, 00:00

  • PHP355 - THE FUTURE OF VALUE-BASED CONTRACTING FOR HIGH-COST INNOVATIVE THERAPIES- GLOBAL LESSONS FROM EUROPE AND THE US

    Oct 1, 2018, 00:00

  • PRM251 - EVALUATING BUDGET IMPACT OF CURES. MACHINE LEARNING METHODS SHED LIGHT ON WHO CAN BE CURED IN METASTATIC MELANOMA

    Oct 1, 2018, 00:00

  • PHP88 - CLINICAL ADDED VALUE ASSESSMENT OF ANTI-INFECTIVES FOR SYSTEMIC USE BY FRENCH TRANSPARENCY COMMITTEE IS CORRELATED WITH THE PUBLIC HEALTH BENEFIT

    Oct 1, 2018, 00:00

  • PRS88 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUANTITATIVE STUDY FINDINGS

    Oct 1, 2018, 00:00

  • PGI26 - COST SAVING ANALYSIS OF A COMMUNITY STOMA CARE SERVICE

    Oct 1, 2018, 00:00

  • PRS62 - PHARMACIST-LED SMOKING CESSATION SERVICES IN RESOURCE LIMITED SETTINGS- A CROSS-SECTIONAL AND SIMULATED STUDY IN ETHIOPIA

    Oct 1, 2018, 00:00

  • PMH5 - HELP-SEEKING BEHAVIOR AND RISK OF SUICIDE ATTEMPT IN HEAVY DRINKERS- RESULTS FROM A NATIONAL 3-YEAR LONGITUDINAL STUDY

    Oct 1, 2018, 00:00

  • PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN288 - HAS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY DRUGS DELIVERED FASTER PATIENT ACCESS TO INNOVATIVE TREATMENTS?

    Oct 1, 2018, 00:00

  • PCV149 - A SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL MYOCARDIAL INFARCTION (MI) OR ACUTE CORONARY SYNDROME (ACS)

    Oct 1, 2018, 00:00

  • PRM244 - USING A PARAMETRIC APPROACH TO SIMULATE THE FREQUENCY OF MIGRAINE HEADACHE DAYS IN PATIENTS WITH CHRONIC MIGRAINE WITH DATA FROM THE REGAIN STUDY

    Oct 1, 2018, 00:00

  • PMU85 - CONSUMER SURVEY OF HEALTH AND RECREATIONAL TOURISM IN THE WEST-TRANSDANUBIAN REGION OF HUNGARY

    Oct 1, 2018, 00:00

  • PMU57 - COST-EFFECTIVENESS OF VACCINATION STRATEGIES TO PREVENT INFECTIOUS DISEASES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • CN3 - VALUE OF ADJUVANT ONCOLOGY THERAPIES- METHODOLOGICAL CHALLENGES OF MODELLING COST-EFFECTIVENESS OF AN ADJUVANT TREATMENT IN AN ERA OF HIGH-COST ONCOLOGY TREATMENTS

    Oct 1, 2018, 00:00

  • PMD70 - ECONOMIC EVALUATION OF THE BURDEN OF PREECLAMPSIA WITHIN AN ITALIAN REGIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PRM104 - EVALUATION OF DATA COLLECTION DURATION IN RETROSPECTIVE NONINTERVENTIONAL MEDICAL RECORD REVIEW ONCOLOGY STUDIES CONDUCTED IN THE UNITED STATES (US), CANADA, UNITED KINGDOM (UK), GERMANY, FRANCE AND SPAIN

    Oct 1, 2018, 00:00

  • PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PRM56 - COULD ERG PREFERENCES FOR DIFFERENT OVERALL SURVIVAL EXTRAPOLATION METHODOLOGIES DRIVE DIFFERENT NICE APPRAISAL OUTCOMES?

    Oct 1, 2018, 00:00

  • PND54 - A LONG TERM ANALYSIS OF THE CLINICAL AND COST EFFECTIVENESS OF GLATIRAMER ACETATE USING FINAL 10-YEAR RESULTS FROM THE UK MULTIPLE SCLEROSIS RISK SHARING SCHEME

    Oct 1, 2018, 00:00

  • PRM162 - A PIECEWISE APPROACH TO THE EXTRAPOLATION OF INVASIVE DISEASE-FREE SURVIVAL (IDFS) IN THE ADJUVANT TREATMENT OF HER2+ BREAST CANCER

    Oct 1, 2018, 00:00

  • CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS- HOW IGNORING THE MODEL’S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)

    Oct 1, 2018, 00:00

  • PCP59 - IDENTIFICATION, SELECTION AND MEASUREMENT OF OUTCOMES TO FACILITATE THE USE OF BIG DATA- A TOOLKIT

    Oct 1, 2018, 00:00

  • PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP301 - THE TIME IS NOW FOR EUROPEAN HTA- HOW WILL THE EVOLUTION OF EUROPEAN HTA IMPACT ACCESS TO INNOVATIVE MEDICINES?

    Oct 1, 2018, 00:00

  • PHP290 - IMPLICATIONS OF CONDITIONAL APPROVAL AND APPROVAL UNDER EXCEPTIONAL CIRCUMSTANCES BY THE EUROPEAN MEDICINES AGENCY ON NICE APPRAISALS

    Oct 1, 2018, 00:00

  • PIN51 - COST-EFFECTIVENESS OF LEDIPASVIR/SOFOBUVIR IN HEPATITIS C TREATMENT- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRM263 - THE USE OF PRISMA STATEMENT IMPROVES THE REPORTING QUALITY OF META-ANALYSES PUBLISHED IN THE FIELD OF PSYCHOLOGY

    Oct 1, 2018, 00:00

  • PMH48 - PHARMACOECONOMIC STUDY OF THE EFFECTIVENESS AND SAFETY OF ANTIPSYCHOTICS

    Oct 1, 2018, 00:00

  • PND152 - IMPACT OF INOTERSEN ON GENERIC HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PSY47 - AN ECONOMIC EVALUATION OF IRON ISOMALTOSIDE 1000 VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN DENMARK

    Oct 1, 2018, 00:00

  • PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK

    Oct 1, 2018, 00:00

  • PSS3 - A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE STUDIES OF INTRAVITREAL AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION

    Oct 1, 2018, 00:00

  • PRM101 - THE COST BURDEN OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PND44 - A NEW APPROACH FOR ESTIMATING AND VISUALISING SOCIETAL COSTS- AN EXAMPLE IN MULTIPLE SCLEROSIS IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY199 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH OBESITY? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PMD74 - HIGH RESOLUTION MELTING FOR THE SCREENING OF RESISTANCE-ASSOCIATED MUTATIONS IN MYCOBACTERIUM LEPRAE IN LEPROSY PATIENTS WITH SUSPECTED RELAPSE ASSOCIATED WITH RESISTANCE.

    Oct 1, 2018, 00:00

  • PRM25 - INCORPORATING EXPERT OPINION TO IMPROVE ESTIMATES OF LONG-TERM SURVIVAL WHEN FOLLOW-UP OF EMPIRICAL STUDIES IS SHORT

    Oct 1, 2018, 00:00

  • PSS12 - PREVALENCE OF NEUROTROPHIC KERATOPATHY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015

    Oct 1, 2018, 00:00

  • PND81 - HEALTH SERVICE USE IN HIGH AND LOW SEVERITY DRAVET SYNDROME IN THE EU5

    Oct 1, 2018, 00:00

  • PND124 - HUMANISTIC AND ECONOMIC BURDEN OF PROGRESSIVE SUPRANUCLEAR PALSY- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM206 - THE PERIODIC SYSTEMATIC REVIEW FOR BIBLIOPRO- A DECADE OF SPANISH PATIENT-REPORTED OUTCOMES.

    Oct 1, 2018, 00:00

  • PSS64 - A PREFERENCE STUDY INVESTIGATING PATIENT CHOICE FOR TREATING SEVERE CHRONIC SPONTANTEOUS/IDIOPATHIC URTICARIA (CSU/CIU)

    Oct 1, 2018, 00:00

  • PHP129 - CHALLENGES AND OPPORTUNITIES IN THE BIOLOGICALS-BIOSIMILARS MARKET- SUSTAINABILITY AND MARKET DIFFERENTIATION

    Oct 1, 2018, 00:00

  • PCV59 - HEALTH INSURANCE COST OF ESSENTIAL (PRIMARY) HYPERTENSION IN HUNGARY- A NATIONWIDE, REAL-WORLD COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PSS8 - IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON-INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS)- THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

    Oct 1, 2018, 00:00

  • PCP3 - ADAPTIVE PATHWAYS 2020- WHAT’S ON THE HORIZON IN THE NEXT 2-3 YEARS?

    Oct 1, 2018, 00:00

  • PRS35 - THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN THE UK HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PND12 - NATALIZUMAB VERSUS GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCV83 - KEY MODEL PARAMETERS AND METHODOLOGIES USED IN COST-EFFECTIVENESS ANALYSIS EVALUATING TREATMENTS FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) OR ACUTE COR ...

    Oct 1, 2018, 00:00

  • PRS20 - HEALTH PLAN COVERAGE OF SMOKING CESSATION TREATMENT WITH DRUG THERAPY IS COST-EFFECTIVE? A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PHP280 - IS THERE A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS?

    Oct 1, 2018, 00:00

  • PCV65 - EXPERT ANALYSIS ON COST ANALYSIS OF MANAGEMENT OF CARDIOVASCULAR DISEASE CO-MORBIDITIES

    Oct 1, 2018, 00:00

  • DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONS

    Oct 1, 2018, 00:00

  • PRM201 - PRESCRIPTION, ILLICIT AND HOMEOPATHIC DRUGS - ISSUES FACED IN LANGUAGE AND CULTURAL RELEVANCE WHEN REFERRING TO MEDICATION IN COAS.

    Oct 1, 2018, 00:00

  • PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PSY176 - SIGNIFICANT BENEFIT AND RELATIVE EFFECTIVENESS ASSESSMENT OF ORPHAN MEDICINAL PRODUCTS IN THE EUROPEAN UNION- A COMPARATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PND65 - COST-EFFECTIVENESS ANALYSIS OF DRUGS USED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCV25 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PRS96 - PATIENT PERCEIVED IMPACT OF NURSE-LED SELF-MANAGEMENT INTERVENTIONS FOR COPD- A SYSTEMATIC REVIEW OF QUALITATIVE RESEARCH

    Oct 1, 2018, 00:00

  • PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMU92 - CAN THE EQ-5D-3L PREDICT POST-HOSPITALIZATION HEALTHCARE USE AND OUTCOMES?

    Oct 1, 2018, 00:00

  • PRM194 - INVESTIGATING THE RELATIONSHIP BETWEEN AGE AND EXPANDED DISABILITY STATUS SCALE SCORE IN UNTREATED AND CHENODEOXYCHOLIC ACID-TREATED CEREBROTENDINOUS XANTHOMATOSIS PATIENTS

    Oct 1, 2018, 00:00

  • PRM186 - MEASUREMENT PROPERTIES OF TRANSLATED VERSIONS OF MEASURES ASSESSING THE SUBJECTIVE EFFECTS OF TOBACCO- AND NICOTINE-CONTAINING PRODUCTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU79 - THE USE OF NETWORK META-ANALYSIS TO COMPARE DIFFERENT MEASURES OF MEDICATION ADHERENCE

    Oct 1, 2018, 00:00

  • AC3 - DISCORDANT DESIGNATIONS OF BREAKTHROUGH DRUG INNOVATION- FRANCE VERSUS THE UNITED STATES

    Oct 1, 2018, 00:00

  • PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?

    Oct 1, 2018, 00:00

  • PMD149 - CLAVICLE FRACTURE- TREATMENT, COMPLICATIONS, AND COST IN THE COMMERCIALLY-INSURED POPULATION

    Oct 1, 2018, 00:00

  • PMS106 - COMPARISON OF DYNAMIC AND STATIC BALANCE AMONG HUNGARIAN AND FINNISH ADOLESCENT FOOTBALL PLAYERS

    Oct 1, 2018, 00:00

  • PRM124 - MODELLING LIKELY CARDIOVASCULAR DISEASE MORTALITY WITH PCSK9 INHIBITORS USING A SYNTHETIC POPULATION

    Oct 1, 2018, 00:00

  • PCN311 - EUROPEAN MARKET ACCESS CHALLENGES FOR RELAPSED REFRACTORY MULTIPLE MYELOMA TRIPLET THERAPIES

    Oct 1, 2018, 00:00

  • PSS58 - TREATMENT PATTERNS FOR AGE-RELATED MACULAR DEGENERATION IN SPAIN- KEYS FOR IMPROVING MANAGEMENT IN DAILY CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PHP67 - CURRENT INITIATIVES FUTURE OF E-HEALTH FUNDING PATHS

    Oct 1, 2018, 00:00

  • PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACK

    Oct 1, 2018, 00:00

  • PMS58 - ECONOMIC EVALUATION OF ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY IN A TERTIARY HOSPITAL SETTINGS IN HUNGARY- A COST MINIMIZATION STUDY

    Oct 1, 2018, 00:00

  • PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEY

    Oct 1, 2018, 00:00

  • PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKING

    Oct 1, 2018, 00:00

  • PHP283 - PHARMACEUTICAL CARE IN RESIDENTIAL SOCIO-HEALTH CENTERS- OPTIMISATION OF STORAGE AND DISPENSING CIRCUIT

    Oct 1, 2018, 00:00

  • PSY21 - DELETERIOUS EFFECT OF BLOOD TRANSFUSIONS IN A COHORT OF ANAEMIC INPATIENTS

    Oct 1, 2018, 00:00

  • PHP5 - DEVELOPMENT OF THE PATIENT ORGANISATION SUBMISSION PROCESS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE), IRELAND

    Oct 1, 2018, 00:00

  • PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PRS48 - COST – EFFECTIVENESS ANALYSIS OF VILANTEROL/FLUTICASONE FUROATE FOR ASTHMA TREATMENT IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PSY43 - BUDGET IMPACT ANALYSIS OF METHOXYFLURANE (PENTHROX®) FOR EMERGENCY RELIEF OF MODERATE-TO-SEVERE TRAUMA PAIN IN THE SWEDISH SETTING

    Oct 1, 2018, 00:00

  • PGI29 - GENDER DIFFERENCES IN CLINICAL PROFILE AND HEALTHCARE UTILIZATION OF NON ALCOHOLIC FATTY LIVER PATIENTS

    Oct 1, 2018, 00:00

  • PND60 - COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN ...

    Oct 1, 2018, 00:00

  • PIN32 - THE PUBLIC HEALTH AND ECONOMIC IMPACT OF INCREASED SCREENING AND IMMEDIATE INITIATION OF ANTIRETROVIRAL TREATMENT FOR HIV-1 IN THE UK

    Oct 1, 2018, 00:00

  • PHP87 - COULD THE FRENCH COHORT ATU PROGRAM BE THE MODEL EUROPE NEEDS TO HARMONIZE COMPASSIONATE USE PROGRAMS?

    Oct 1, 2018, 00:00

  • PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PMD36 - BUDGET IMPACT ANALYSIS OF THE USE OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA IN ITALY

    Oct 1, 2018, 00:00

  • PMD144 - SELECTIVE HEALTH BENEFIT TO REDUCE ECONOMIC BURDEN OF PATIENTS- CASE OF CANCER SURGERY

    Oct 1, 2018, 00:00

  • PRM275 - FIELD RESEARCH FOR THE DETERMINATION OF THE INDIRECT COSTS OF PERITONEAL DIALYSIS AND HEMODIALYSIS IN TURKEY

    Oct 1, 2018, 00:00

  • PHP325 - ORPHAN DRUGS‘ MARKET ACCESS CHALLENGES IN EUROPE FROM A GERMAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY200 - PATIENT-REPORTED OUTCOMES MEASURES IN CHILDREN WITH SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PCN393 - THE BURDEN OF INFORMAL CARE FOR BREAST CANCER PATIENTS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY- A BUDGET IMPACT ANALYSIS

    Oct 1, 2018, 00:00

  • PSY192 - PATIENT HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH REMISSION OF ATTP, A REGRESSION ANALYSIS USING NON-RANDOMISED OBSERVATIONAL DATA FROM THE OKLAHOMA TTP REGISTRY

    Oct 1, 2018, 00:00

  • PDB133 - CHRONIC KIDNEY DISEASE, HEALTH MEASURES AND HEALTHCARE UTILIZATION AMONG ADULTS WITH DISBETES IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PHP57 - EUROPEAN CONDITIONAL MARKETING AUTHORIZATION – DOES EARLY MARKETING AUTHORIZATION TRANSLATE INTO EARLY REIMBURSEMENT AND PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PCN314 - HEALTH-TECHNOLOGY ASSESSMENTS IN ONCOLOGY- RESULTS OF A REVIEW OF DECISIONS IN GERMANY

    Oct 1, 2018, 00:00

  • PCV52 - COST COMPARISON- STRATEGIES OF PATIENTS MANAGEMENT IN ORAL ANTICOAGULANT THERAPY

    Oct 1, 2018, 00:00

  • PCV66 - COSTS OF EARLY REHABILITATION AFTER STROKE IN CZECH CEREBROVASCULAR CENTERS

    Oct 1, 2018, 00:00

  • PRM59 - DEVELOPING A MODELLING FRAMEWORK TO ASSESS THE COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS

    Oct 1, 2018, 00:00

  • PSY132 - ECONOMIC CRISIS AND THE EFFECT ON PHARMACOECONOMICS IN A REGIONAL GENERAL HOSPITAL

    Oct 1, 2018, 00:00

  • PSY32 - CLAIMS-BASED ANALYSIS OF HOMOCYSTEINE TESTING, ELEVATED HOMOCYSTEINE LEVELS, AND HOMOCYSTINURIA DIAGNOSIS IN THE U.S.

    Oct 1, 2018, 00:00

  • PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5

    Oct 1, 2018, 00:00

  • PRM10 - METHODOLOGICAL ASSESSMENT OF ECONOMIC ANALYSES ON COMPUTERIZED PHYSICIAN ORDER ENTRY SYSTEMS AND RELATED CLINICAL DECISION SUPPORT TOOLS IN INPATIENT CARE

    Oct 1, 2018, 00:00

  • PND114 - IMPACT OF A PHARMACIST-LED COMMUNITY INTERVENTIONAL PROGRAM TO PREVENT COGNITIVE DETERIORATION IN COMMUNITY-DWELLING HONG KONG ELDERS WITH HIGH ANTICHOLINERGIC COGNITIVE BURDEN

    Oct 1, 2018, 00:00

  • PND29 - LONG RANGE SIMULATION OF THE COST BURDEN OF DIFFERENCE TREATMENT SEQUENCES APPROVED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP318 - EXPERIENCE WITH EARLY DIALOGUES (ED) IN EUNETHTA JA3

    Oct 1, 2018, 00:00

  • PRM236 - CALIBRATING MATCHING ADJUSTED INDIRECT COMPARISON ESTIMATE TO REAL-WORLD POPULATION

    Oct 1, 2018, 00:00

  • PHP41 - IMPACT OF PRICE REGULATION ORDINANCE ON TOP 20 PRESCRIBED MEDICINES PRICES IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PMH1 - PATIENT-REPORTED SIDE EFFECTS OF BUPRENORPHINE-NALOXONE- IDENTIFYING INDEPENDENT PREDICTORS FROM PATIENT VIEWS AND CLINICAL ASSESSMENT DURING MAINTENANCE TREATMENT OF HEROIN USE DISORDER

    Oct 1, 2018, 00:00

  • PDB9 - ASSOCIATION BETWEEN CLASS OF ANTIDIABETIC DRUGS AND INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELITUS- A PROPORTIONAL HAZARD ANALYSIS USING DEEP LEARNING FOR RISK ADJUSTMENT

    Oct 1, 2018, 00:00

  • PDB4 - THE EFFECT OF STATINS USAGE ON DIABETIC EYE COMPLICATIONS

    Oct 1, 2018, 00:00

  • HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT

    Oct 1, 2018, 00:00

  • PMH6 - LURASIDONE INDUCED SUICIDAL IDEATION AND HALLUCINATION- DISPROPORTIONALITY ANALYSIS IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME- POPULATION-BASED DATA FROM THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PRM62 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS BASED ON DECISION-ANALYTIC MODELING OF CANCER DRUGS

    Oct 1, 2018, 00:00

  • PMD171 - HEALTH TECHNOLOGY ASSESSMENT OF COMPANION DIAGNOSTICS ALONGSIDE THERAPEUTC AGENTS IN ONCOLOGY- EXPERIENCE OF THE NICE TECHNOLOGY APPRAISAL PROGRAMME

    Oct 1, 2018, 00:00

  • PCV36 - ESTIMATION OF THE INCREASED RISK ASSOCIATED WITH RECURRENT EVENTS OR POLY-VASCULAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN THE UNITED KINGDOM FOR USE IN ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PGI12 - PREDICTORS OF READMISSION FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION USING THE FRENCH HEALTH INSURANCE DATABASE

    Oct 1, 2018, 00:00

  • PHP293 - ORPHAN DRUGS IN GERMANY - LESSONS LEARNED FROM AMNOG, BEST AND WORST PRACTICES AND STRATEGIC IMPLICATIONS

    Oct 1, 2018, 00:00

  • PCN348 - QUALITY OF LIFE IN END-STAGE CANCER DISEASE

    Oct 1, 2018, 00:00

  • PCN340 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (VMP) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) INELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

    Oct 1, 2018, 00:00

  • PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCV157 - ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND ATRIAL FIBRILLATION SYMPTOM BURDEN- RESULTS OF A STUDY ON ATRIAL FIBRILLATION PATIENTS IN GERMANY, SWEDEN AND SWITZERLAND

    Oct 1, 2018, 00:00

  • PDB13 - SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETES

    Oct 1, 2018, 00:00

  • PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELAND

    Oct 1, 2018, 00:00

  • PCN380 - THE PROGNOSTIC SIGNIFICANCE OF HEALTH-RELATED QUALITY OF LIFE FROM CANCER RANDOMIZED CONTROLLED TRIALS- A SYSTEMATIC EVALUATION OF THE STATISTICAL METHODS

    Oct 1, 2018, 00:00

  • PMD96 - THE IMPACT OF STRUCTURAL ASSUMPTIONS ON DECISION UNCERTAINTY- A CASE STUDY ON THE PREVENTION OF NEONATAL INFECTIONS IN PRETERM BABIES

    Oct 1, 2018, 00:00

  • PSY87 - ECONOMIC BURDEN OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY

    Oct 1, 2018, 00:00

  • PMS53 - VALIDATION IN A REAL WORLD SCENARIO OF A CLINICAL DECISION SUPPORT SYSTEM FOR THE PREVALENCE, FRACTURE RISKS AND TREATMENT OF OSTEOPOROSIS IN THE BRAZILIAN PRIVATE MARKET

    Oct 1, 2018, 00:00

  • PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PRM203 - LINGUISTIC VALIDATION OF THE CHRONIC KIDNEY DISEASE AND ANAEMIA QUESTIONNAIRE (CKDAQ), A PATIENT REPORT OUTCOMES ASSESSMENT (PRO), INTO 30 ASIA-PACIFIC LANGUAGES

    Oct 1, 2018, 00:00

  • PHP260 - A EUROPEAN ANALYSIS OF FIXED DOSE COMBINATIONS PRICE SETTING

    Oct 1, 2018, 00:00

  • PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES- A DOCUMENTARY ANALYSIS

    Oct 1, 2018, 00:00

  • PSY28 - EPIDEMIOLOGY OF RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSS18 - TREATMENT COSTS OF ATOPIC DERMATITIS IN KOREAN ADULTS ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PSS11 - PATIENTS UNDER ATOPIC DERMATITIS TREATMENT IN PORTUGAL- RESULTS FROM A PHYSICIANS’ SURVEY

    Oct 1, 2018, 00:00

  • PIN104 - MENINGOCOCCAL GROUP B (MENB) VACCINE SERIES COMPLETION AND COMPLIANCE AMONG COMMERCIALLY-INSURED INDIVIDUALS AGED 16-23 IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PRM123 - AN OVERVIEW OF OPEN-SOURCE MODELS IN HEALTH ECONOMICS

    Oct 1, 2018, 00:00

  • PND9 - MIGRAINE BURDEN BEFORE AND AFTER ERENUMAB TREATMENT- A RESPONDER ANALYSIS IN DIFFICULT-TO-TREAT PATIENTS

    Oct 1, 2018, 00:00

  • PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMAB

    Oct 1, 2018, 00:00

  • PMU13 - REALIZING TRANSPARENCY- REGISTRATION OF REAL-WORLD EVIDENCE STUDIES OF TREATMENT AND/OR COMPARATIVE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCV154 - ASSESSING DIFFERENTIAL ATTRIBUTES OF DIRECT ORAL ANTICOAGULANTS WITH IMPACT ON PATIENT PREFERENCES. A PILOT STUDY

    Oct 1, 2018, 00:00

  • PND46 - ECONOMIC BURDEN OF FRAGILE X SYNDROME IN EUROPE AND THE US- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCP10 - PATIENT ACCESS TO NEW MEDICINES; THE CHANGING LANDSCAPE

    Oct 1, 2018, 00:00

  • PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5

    Oct 1, 2018, 00:00

  • PHP185 - BRAZIL'S ECONOMIC SITUATION AND THE EVOLUTION OF THE PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN207 - NEW DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS

    Oct 1, 2018, 00:00

  • PMD15 - COMPUTER-ASSISTED (TAONET®) AND MANUAL DOSAGE CONTROL OF PATIENTS ON ORAL ANTICOAGULANT THERAPY IN ROUTINE CLINICAL PRACTICE. PRELIMINARY RESULTS OF A MULTICENTER STUDY

    Oct 1, 2018, 00:00

  • PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES- COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINES

    Oct 1, 2018, 00:00

  • PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM- A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCE

    Oct 1, 2018, 00:00

  • PCN162 - DENOSUMAB VERSUS BISPHOSPHONATES FOR THE TREATMENT OF BONE METASTASES FROM SOLID TUMORS- A SYSTEMATIC REVIEW OF ECONOMIC STUDIES

    Oct 1, 2018, 00:00

  • PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015

    Oct 1, 2018, 00:00

  • PCN125 - FIRST INSIGHTS INTO COMPARING EXPENDITURES FOR TARGETED THERAPY AND SURVIVAL IN NSCLC

    Oct 1, 2018, 00:00

  • PSY137 - ORPHAN DRUG ACCESS AND REIMBURSEMENT IN THE EU5- CYSTIC FIBROSIS AND DUCHENNE MUSCULAR DYSTROPHY

    Oct 1, 2018, 00:00

  • PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLAND

    Oct 1, 2018, 00:00

  • PMD44 - COST COMPARISON OF RECHARGEABLE AND NON-RECHARGEABLE DEEP BRAIN STIMULATION DEVICES IN THE NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PHP368 - THE FRENCH COMPASSIONATE USE OF MEDICINAL PRODUCTS PROGRAM (2012-2017)- HEALTH TECHNOLOGY ASSESSMENT AND PRICING IMPLICATIONS

    Oct 1, 2018, 00:00

  • PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PHP164 - PHARMACEUTICAL POLICIES IN PORTUGAL – TRENDS AND IMPACT

    Oct 1, 2018, 00:00

  • PMU70 - PRESCRIPTION ANALYSIS OF HYPOCALORIC PERIPHERAL PARENTERAL NUTRITION AT A TERTIARY CARE HOSPITAL

    Oct 1, 2018, 00:00

  • PHP101 - SOCIO-ECONOMIC AND SOCIO-DEMOGRAPHIC DRIVERS INFLUENCING PREVALENCE OF ANTIBIOTIC USE- AN ANALYSIS IN SOUTHERN ITALY SETTING

    Oct 1, 2018, 00:00

  • PMD162 - AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) NEWBORN SCREENING (NBS) RECOMMENDATIONS- SENSITIVITY TO ACCOUNTING FOR REPORTED MISSING DATA IN THE CASE OF GLUTARIC ACIDURIA II (GAII)

    Oct 1, 2018, 00:00

  • PSY140 - DEXMEDETOMIDINE UTILISATION STUDY IN THE INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PCN346 - DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES

    Oct 1, 2018, 00:00

  • PND79 - REDUCED HEALTHCARE RESOURCE UTILISATION FOR PATIENTS TREATED WITH DELAYED RELEASE DIMETHYL FUMARATE VS INJECTABLE THERAPIES- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY OF MS PATIENTS

    Oct 1, 2018, 00:00

  • PMS26 - COMPARATIVE TREATMENT COSTS OF SURGICAL VS NON-SURGICAL PATIENTS WITH MEDIAL MENISCUS DEFICIENCY- RESULTS FROM A 24-MONTH SURVEILLANCE STUDY

    Oct 1, 2018, 00:00

  • PRM253 - EXPLORATION OF NETOWRK META-REGRESSION MODELS APPLIED TO COMPLEX EVIDENCE NETWORKS

    Oct 1, 2018, 00:00

  • PCN243 - POST-LOE PRICING DYNAMICS IN ONCOLOGY- IMPACT OF MANDATORY PRICE DISCOUNTS ON LIST PRICES AND GENERIC UPTAKE

    Oct 1, 2018, 00:00

  • PSY78 - THE ECONOMIC AND HEALTHCARE BURDEN OF ANCA-ASSOCIATED VASCULITIS (AAV) IN GERMANY

    Oct 1, 2018, 00:00

  • PHP138 - CHANGES IN THE NUMBER OF MIDWIVES IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PRM198 - STANDARD ERROR OF MEASUREMENT AND SMALLEST DETECTABLE CHANGE OF THE SARQOL® QUESTIONNAIRE- AN ANALYSIS OF SUBJECTS FROM 8 VALIDATION STUDIES

    Oct 1, 2018, 00:00

  • PGI19 - STANDARD-DOSE PROTON PUMP INHIBITOR IN THE INITIAL NON-ERADICATION TREATMENT OF DUODENAL ULCER- SYSTEMATIC REVIEW, NETWORK META-ANALYSIS, AND COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PRS25 - A RETROSPECTIVE DATABASE STUDY TO DEFINE A PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENT COHORT AND EVALUATE THE ECONOMIC BURDEN OF ILLNESS IN FRANCE

    Oct 1, 2018, 00:00

  • PCV106 - EVALUATION OF PRICES AND SALES VOLUME OF CARDIO-VASCULAR MEDICINES IN COMMUNITY PHARMACIES

    Oct 1, 2018, 00:00

  • PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REAL

    Oct 1, 2018, 00:00

  • PDB134 - CHARACTERISTICS OF US ADULTS WITH CONTROLLED AND UNCONTROLLED TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PHP340 - UNDERSTANDING PHYSICIANS’ CONCEPTION OF QUALITY OF HEALTH CARE DELIVERY- AN EXPLORATIVE STUDY USING THE REPERTORY GRID TECHNIQUE

    Oct 1, 2018, 00:00

  • PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?

    Oct 1, 2018, 00:00

  • PMD102 - COST-EFFECTIVENESS OF USING [18F]FLUTEMETAMOL IN THE CLINICAL EVALUATION OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR SUSPECTED DEMENTIA IN SPAIN

    Oct 1, 2018, 00:00

  • PHP120 - WHAT DO WE STAND TO LOSE? THE PROPORTION OF US-OWNED PHARMACEUTICALS ON AUSTRALIA’S PHARMACEUTICAL BENEFITS SCHEME

    Oct 1, 2018, 00:00

  • PRM122 - BOOTSTRAPPING PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL TO CAPTURE THEIR CORRELATION IN PROBABILISTIC SENSITIVITY ANALYSES

    Oct 1, 2018, 00:00

  • PND68 - COST-EFFECTIVENESS OF TERIFLUNOMIDE COMPARED TO INTERFERON BETA-1B FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD8 - COMPARATIVE ASSESSMENT OF MEASURING TECHNIQUES OF CHILDREN’S TEMPERATURE IN PEDIATRIC DEPARTMENT

    Oct 1, 2018, 00:00

  • PND39 - MULTIPLE SCLEROSIS BURDEN OF ILLNESS STUDY FOR TURKEY

    Oct 1, 2018, 00:00

  • PSY110 - PHARMACOECONOMICS OF DIFFERENT TREATMENTS FOR STEROID-REFRACTORY GRAFT VERSUS HOST REACTION- ANALYSIS OF TREATMENT RESULTS IN A SINGLE-CENTER STUDY

    Oct 1, 2018, 00:00

  • PMU117 - MEASURING IMPROVEMENT IN HEALTH-STATUS WITH THE OXFORD PARTICIPATION AND ACTIVITIES QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • CE2 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Oct 1, 2018, 00:00

  • CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOW

    Oct 1, 2018, 00:00

  • PCP21 - BIOSIMILARS IN THE UK – A 2018 UPDATE

    Oct 1, 2018, 00:00

  • PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATION

    Oct 1, 2018, 00:00

  • PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS- AN ONTARIO, CANADA ANALYSIS

    Oct 1, 2018, 00:00

  • PCV110 - TREATMENT WITH FREE TRIPLE COMBINATION THERAPY OF ATORVASTATIN, PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN PATIENTS WITH HYPERTENSION- A REAL-WORLD POPULATION STUDY IN ITALY.

    Oct 1, 2018, 00:00

  • PGI35 - ASSESSMENT OF ANTISECRETORY DRUGS CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Oct 1, 2018, 00:00

  • PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE

    Oct 1, 2018, 00:00

  • PND3 - SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS IN PAEDIATRIC PATIENTS WITH FOCAL SEIZURES – ARE CURRENTLY APPROVED THERAPIES SUFFICIENT FOR THE MANAGEMENT OF PAEDIATRIC PATIENTS?

    Oct 1, 2018, 00:00

  • PSS46 - DIFFERENCES IN HTA COVERAGE RECOMMENDATIONS- COMPARING OPHTHALMOLOGY DRUG REIMBURSEMENT DECISIONS IN FOUR EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PRM163 - AN APPROACH TO EVALUATING THE EFFECT OF PRIORS IN NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICO

    Oct 1, 2018, 00:00

  • PND59 - COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PRS68 - HEALTH RESOURCE UTILIZATION (HRU) AMONG INFANTS DIAGNOSED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE NETHERLANDS- A RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING- SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PMD186 - COMPARATIVE ASSESSMENT OF BODY TEMPERATURE MEASURING TECHNIQUES IN FEVERED CHILDREN AT PAEDIATRIC DEPARTMENT

    Oct 1, 2018, 00:00

  • PMD64 - THE ROLE OF INFORMATION PROVISION IN ECONOMIC EVALUATIONS OF NON-INVASIVE PRENATAL TESTING- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMEN

    Oct 1, 2018, 00:00

  • PRS66 - ANALYSIS OF INDICATORS OF AVAILABILITY AND CONSUMPTION ANTIHISTAMIN PREPARATIONS IN UKRAINE IN 2017

    Oct 1, 2018, 00:00

  • PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE

    Oct 1, 2018, 00:00

  • PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESS

    Oct 1, 2018, 00:00

  • PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN’S LYMPHOMA

    Oct 1, 2018, 00:00

  • PMU103 - INCORPORATING PSYCHOLOGICAL CONSTRUCTS INTO PATIENT PREFERENCE STUDIES- WHICH YOU SHOULD CONSIDER INCLUDING IN YOUR NEXT STUDY?

    Oct 1, 2018, 00:00

  • PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINA

    Oct 1, 2018, 00:00

  • PND113 - HEALTH TECHNOLOGY ASSESSMENT OF MRGFUS FOR THE TREATMENT OF ESSENTIAL TREMOR IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPM

    Oct 1, 2018, 00:00

  • CV4 - PATIENT AND CAREGIVER INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PMH41 - COST-UTILITY ANALYSES OF INFORMAL CAREGIVER INTERVENTIONS- A CRITICAL REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PRM261 - INCORPORATION OF OBSERVATIONAL DATA INTO NETWORK META-ANALYSIS- A CASE STUDY

    Oct 1, 2018, 00:00

  • PMD132 - REAL-WORLD ECONOMIC AND CLINICAL OUTCOMES FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING RADIOFREQUENCY ABLATION USING THERMOCOOL® SF CATHETER VERSUS THERMOCOOL® CATHETER

    Oct 1, 2018, 00:00

  • PRM79 - WEBER EFFECT- AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

    Oct 1, 2018, 00:00

  • PRM195 - THE INFANT GASTROESOPHAGEAL REFLEX DISEASE QUESTIONNAIRE (I-GERQ-R)- A META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIA

    Oct 1, 2018, 00:00

  • PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIA

    Oct 1, 2018, 00:00

  • PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

    Oct 1, 2018, 00:00

  • PRM99 - TRENDS IN OPIOID PRESCRIBING IN PRIMARY CARE PHYSICIAN OFFICES IN THE UNITED STATES- 2006-2015

    Oct 1, 2018, 00:00

  • PHP328 - REAL-WORLD-DATA AND REAL-WORLD-EVIDENCE STATE OF ART FROM A LITERATURE REVIEW PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD89 - COST-EFFECTIVENESS OF OXIGEN THERAPY WITH C-PAP FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA) VERSUS THE STANDARD OF CARE IN THE MEXICAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2018, 00:00

  • PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PSY11 - REAL-WORLD EXPERIENCE OF GENERALIZED LIPODYSTROPHY PATIENTS ENROLLED IN THE METRELEPTIN EARLY ACCESS PROGRAM- INITIAL RESULTS

    Oct 1, 2018, 00:00

  • PHP349 - THE EVOLUTION OF STANDARD MONITORING REGISTRIES IN THE ITALIAN MARKET

    Oct 1, 2018, 00:00

  • PMS66 - IMPROVING PATIENT AND FINANCIAL OUTCOMES IN THE NHS- EARLY ARTHRITIS SERVICE INCREASES PATIENT SATISFACTION WHILST SAVING COSTS

    Oct 1, 2018, 00:00

  • PCV161 - FOCUS ON LIFE QUALITY IN RECONSTRUCTION VASCULAR SURGERY

    Oct 1, 2018, 00:00

  • PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTING

    Oct 1, 2018, 00:00

  • PIH22 - ECONOMIC IMPACT OF DONOR HUMAN MILK VERSUS FORMULA FOR VERY LOW BIRTH WEIGHT INFANTS IN THE NEONATAL INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINA

    Oct 1, 2018, 00:00

  • PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCP54 - OVERVIEW OF METHODS FOR ASSESSING COMPARATIVE EVIDENCE FOR TREATMENTS EVALUATED IN EARLY PHASE TRIALS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PRM173 - DISCRIMINATIVE VALIDITY OF THE EQ-5D-5L AND SF-12 IN OLDER ADULTS WITH ARTHRITIS

    Oct 1, 2018, 00:00

  • PRM105 - REAL WORLD EVIDENCE- DOES THE POPULARITY OF THE TERM REFLECT IN PUBLICATION NUMBERS?

    Oct 1, 2018, 00:00

  • PSY18 - RAPID IMPROVEMENTS IN MOTOR FUNCTION IN SPINAL MUSCULAR ATROPHY TYPE 1 FOLLOWING AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC)- RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

    Oct 1, 2018, 00:00

  • PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP228 - THE IMPACT OF LABEL EXTENSIONS ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ASSESSED ACCORDING TO §35A SGB V IN GERMANY - ONCOLOGICAL AND METABOLIC DISEASES

    Oct 1, 2018, 00:00

  • PND150 - IMPACT OF INOTERSEN ON CONDITION-SPECIFIC QUALITY OF LIFE (QOL) FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PRS26 - THE ECONOMIC BURDEN OF ASTHMA IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTS

    Oct 1, 2018, 00:00

  • PRM245 - EXTRAPOLATION OF SURVIVAL IN THE CONTEXT OF ECONOMIC MODELLING USING BAYESIAN MODEL AVERAGING- AN APPLICATION IN RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMD86 - POTENTIAL COST-EFFECTIVENESS OF SPECTRAL PHOTON-COUNTING COMPUTED TOMOGRAPHY (SPCCT) VERSUS CT COMBINED TO CT ANGIOGRAPHY (CTA) IN THE IDENTIFICATION AND TREATMENT OF ISCHAEMIC STROKE PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAIN

    Oct 1, 2018, 00:00

  • PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PRS101 - IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON QUALITY OF LIFE- FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCP17 - IMPACT OF THE ICER VALUE ASSESSMENT FRAMEWORK ON DRUG PRICING IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS

    Oct 1, 2018, 00:00

  • PSY125 - PHYSICIANS' AND PHARMACISTS’ PRIORITIES IN TREATMENT DECISION-MAKING FOR CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2018, 00:00

  • PDB98 - TYPE 2 DIABETES- REAL-LIFE STUDY BASED ON SNIIRAM DATA OF PATIENTS INITIATING AGLP1 IN 2016

    Oct 1, 2018, 00:00

  • PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE- A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY

    Oct 1, 2018, 00:00

  • PHP54 - DIRECTIVE 2004/18/EC- IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE

    Oct 1, 2018, 00:00

  • PSY86 - HIGHER LEVELS OF SKIN CLEARANCE ARE ASSOCIATED WITH DECREASED INDIRECT COSTS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIES

    Oct 1, 2018, 00:00

  • PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN

    Oct 1, 2018, 00:00

  • PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017

    Oct 1, 2018, 00:00

  • PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PRS51 - COMPARISON OF THE TREATMENT OPTIONS FOR COW'S MILK PROTEIN ALLERGY- A COST MINIMIZATION ANALYSIS BASED ON REAL WORLD CONDITIONS OF TURKEY

    Oct 1, 2018, 00:00

  • PRM228 - EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION- IMPLEMENTATION OF GUYOT’S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMH67 - COMPLIANCE WITH ANTIDEPRESSANT MEDICATION IN KOREA- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PND104 - RECOMMENDATIONS FOR A NATIONAL MULTIPLE SCLEROSIS (MS) STRATEGY

    Oct 1, 2018, 00:00

  • PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMS34 - THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN- RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS)

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PMU37 - INTRODUCTION RATE OF NEW HEMATO-ONCOLOGY DRUGS IN CATALONIA

    Oct 1, 2018, 00:00

  • PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS- THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTS

    Oct 1, 2018, 00:00

  • PND38 - ECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN PATIENTS WITH LOW PHYSICAL DISABILITY

    Oct 1, 2018, 00:00

  • PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLAND

    Oct 1, 2018, 00:00

  • PUK17 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE

    Oct 1, 2018, 00:00

  • CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PSY113 - ASSESSMENT OF BASIC HEALTH TECHNOLOGIES FOR ACROMEGALY PHARMACOTHERAPY IN UKRAINE

    Oct 1, 2018, 00:00

  • PRM260 - GENERATION OF RECONSTRUCTED INDIVIDUAL PATIENT DATA FROM DIGITIZED CURVES IN COST-EFFECTIVENESS MODEL- A DISCRETE OPTIMIZATION APPROACH

    Oct 1, 2018, 00:00

  • PMS113 - TOWARD PATIENT-CENTERED VALUE ASSESSMENT- LESSONS FROM THE IVI OPEN-SOURCE VALUE PROJECT

    Oct 1, 2018, 00:00

  • PRS31 - THE ECONOMIC IMPACT OF OPTIMIZED POST-HOSPITALIZATION MANAGEMENT FOR AN EXACERBATION IN COPD PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PMD17 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN BARBED AND CONVENTIONAL SUTURES AMONG PATIENTS UNDERGOING SPINE SURGERY

    Oct 1, 2018, 00:00

  • PIN86 - COST SAVINGS TO BE EXPECTED FROM THE INTRODUCTION OF NEW ANTI-HIV GENERICS IN UNIVERSITY PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PMD45 - BIOMARKER-GUIDED RISK ASSESSMENT OF ACUTE KIDNEY INJURY- RESULTS OF A COSTING MODEL FROM A UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM141 - COMPARISON OF NOVEL BAYESIAN METHODS USING EXTERNAL DATA TO IMPROVE SURVIVAL ESTIMATIONS FROM IMMATURE SURVIVAL DATA

    Oct 1, 2018, 00:00

  • PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PMH50 - TREATMENT OF OPIOID USE DISORDER IN ITALY- IS THERE SCOPE FOR POLICY CHANGE?

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKE

    Oct 1, 2018, 00:00

  • PRM269 - SYSTEMATIC LITERATURE REVIEW (SLR) EVALUATING QUALITY ASSESSMENT TOOLS (QAT)

    Oct 1, 2018, 00:00

  • PMS111 - PATIENTS’ PREFERENCES FOR TREATMENT OF PSORIATIC ARTHRITIS BASED ON A DISCRETE CHOICE EXPERIMENT. RESULTS OF THE COEPSO STUDY

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63 (current)
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • »